Equity Profile

TEVA

Teva Pharmaceutical Industries Limited

Health CarePharmaceuticals$42.6B

Jul29Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Teva Pharmaceutical Industries Limited is a global leader in the pharmaceutical sector, specializing in generic and specialty medicines. With a market cap of $43 billion, Teva plays a crucial role in providing affordable healthcare solutions, particularly as the industry faces increasing pressure for cost-effective treatments.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating income.

$0.70

Revenue

Total revenue reflects the company's ability to sell its products and services, which is vital for assessing growth and market demand.

$4.2B

Wall Street expectations, options signals, track record, and call prep available with Pro.

TEVA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+15.61%

Avg Stock Reaction

+3.79%

Last Quarter Recap

In Q1 2026, Teva reported an EPS of $0.53, exceeding expectations by 8.83%. The stock reacted positively, gaining nearly 12% the following day.

Management Promises & Guidance

Continue focusing on cost management to improve margins.
Expand the portfolio of specialty medicines.
Enhance operational efficiencies across manufacturing.

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about Teva's upcoming earnings, expecting a solid performance based on recent trends.

Bull Case

If Teva beats EPS estimates, it could signal strong operational improvements and renewed investor confidence, potentially driving the stock higher.

Bear Case

Conversely, if earnings fall short, it may raise concerns about the company's growth trajectory and cost management, leading to a negative market reaction.

Key Metrics to Watch

EPS

$0.70

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating income.

Revenue

$4.2B

Total revenue reflects the company's ability to sell its products and services, which is vital for assessing growth and market demand.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed the consensus estimate of $0.70?

A beat on EPS would reinforce confidence in Teva's operational efficiency and growth strategy.

What is the outlook for revenue growth in the specialty medicines segment?

Insights into this segment could indicate future profitability and market positioning.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Teva's ability to improve margins through cost management, which could lead to better-than-expected earnings.

Supporting Evidence

Teva has consistently beaten EPS estimates in recent quarters, suggesting operational strength.

The options market is pricing a smaller move than historical averages, indicating potential for a surprise.

Recent operational improvements may not be fully reflected in analyst forecasts.

Key Risk

If Teva demonstrates significant margin improvement, it could invalidate current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on Teva's ability to meet or exceed earnings expectations, particularly in light of recent operational improvements.

Bull Confirmed If

An EPS of $0.74 or higher would confirm strong operational performance.

Bear Confirmed If

An EPS below $0.60 would raise significant concerns about growth and cost management.

Pre-Earnings Positioning

Options Market

Implied Move

±5.66%

Historical Avg

±9.0%

Pricing cheap

The options market is pricing in a moderate move around the earnings report, suggesting uncertainty about the results.

Options are pricing ±5.7% while TEVA has averaged ±9.0% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.4%

30d HV

39.9%

Calls (108K)P/C Ratio: 0.30Puts (114K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Teva beats expectations, history suggests a potential stock increase of around 3.79%, confirming positive operational trends.

In-Line / Cautious

A report in line with expectations may lead to a muted response, as investors await further clarity on future guidance.

Miss

Should earnings fall short, the stock could decline, with historical patterns indicating a potential drop of around 3.79%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on cost management strategies and their impact on margins.
2Details on the performance of specialty medicines and future growth prospects.
3Management's commentary on competitive pressures in the pharmaceutical market.
4Insights into regulatory challenges and their potential impact on revenue.
5Guidance on future earnings expectations and strategic initiatives.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating income.

$0.70

Revenue

Total revenue reflects the company's ability to sell its products and services, which is vital for assessing growth and market demand.

$4.2B

Wall Street expectations, options signals, track record, and call prep available with Pro.

TEVA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+15.61%

Avg Stock Reaction

+3.79%

Last Quarter Recap

In Q1 2026, Teva reported an EPS of $0.53, exceeding expectations by 8.83%. The stock reacted positively, gaining nearly 12% the following day.

Management Promises & Guidance

Continue focusing on cost management to improve margins.
Expand the portfolio of specialty medicines.
Enhance operational efficiencies across manufacturing.

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about Teva's upcoming earnings, expecting a solid performance based on recent trends.

Bull Case

If Teva beats EPS estimates, it could signal strong operational improvements and renewed investor confidence, potentially driving the stock higher.

Bear Case

Conversely, if earnings fall short, it may raise concerns about the company's growth trajectory and cost management, leading to a negative market reaction.

Key Metrics to Watch

EPS

$0.70

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating income.

Revenue

$4.2B

Total revenue reflects the company's ability to sell its products and services, which is vital for assessing growth and market demand.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed the consensus estimate of $0.70?

A beat on EPS would reinforce confidence in Teva's operational efficiency and growth strategy.

What is the outlook for revenue growth in the specialty medicines segment?

Insights into this segment could indicate future profitability and market positioning.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Teva's ability to improve margins through cost management, which could lead to better-than-expected earnings.

Supporting Evidence

Teva has consistently beaten EPS estimates in recent quarters, suggesting operational strength.

The options market is pricing a smaller move than historical averages, indicating potential for a surprise.

Recent operational improvements may not be fully reflected in analyst forecasts.

Key Risk

If Teva demonstrates significant margin improvement, it could invalidate current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on Teva's ability to meet or exceed earnings expectations, particularly in light of recent operational improvements.

Bull Confirmed If

An EPS of $0.74 or higher would confirm strong operational performance.

Bear Confirmed If

An EPS below $0.60 would raise significant concerns about growth and cost management.

Pre-Earnings Positioning

Options Market

Implied Move

±5.66%

Historical Avg

±9.0%

Pricing cheap

The options market is pricing in a moderate move around the earnings report, suggesting uncertainty about the results.

Options are pricing ±5.7% while TEVA has averaged ±9.0% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.4%

30d HV

39.9%

Calls (108K)P/C Ratio: 0.30Puts (114K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Teva beats expectations, history suggests a potential stock increase of around 3.79%, confirming positive operational trends.

In-Line / Cautious

A report in line with expectations may lead to a muted response, as investors await further clarity on future guidance.

Miss

Should earnings fall short, the stock could decline, with historical patterns indicating a potential drop of around 3.79%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on cost management strategies and their impact on margins.
2Details on the performance of specialty medicines and future growth prospects.
3Management's commentary on competitive pressures in the pharmaceutical market.
4Insights into regulatory challenges and their potential impact on revenue.
5Guidance on future earnings expectations and strategic initiatives.